Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MARRONE BIO INNOVATIONS, INC.

(MBII)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Marrone Bio Acquires Jet Ag and Jet Oxide Product Lines; Significantly Expands Opportunity in Agricultural Bioprotection Market

09/11/2019 | 08:32am EDT

DAVIS, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Marrone Bio Innovations Inc. (NASDAQ: MBII), a leading developer of bio-based products for pest management and plant health, has acquired from Jet Harvest Solutions all rights and assets to the Jet Ag and Jet Oxide product lines.  Jet Ag and Jet Oxide are broad-spectrum products used both for control of fungal and bacterial diseases and as disinfectants.

The transaction builds on a two-year relationship and prior distribution agreement between Jet Harvest and Marrone Bio. Going forward, the portfolio will be sold through Marrone Bio’s existing sales force and distribution network except for the post-harvest business, which has been licensed back to Jet Harvest Solutions.

With gross margins in line with Marrone Bio’s current portfolio of products, the Jet Ag and Jet Oxide product lines are expected to add to the company’s revenues in 2019 and be accretive to earnings within two years.  The purchase price for the assets is approximately $2.5 million in cash, plus five yearly earn-out payments based on certain sales. In addition, Marrone Bio engaged the founders of Jet Harvest Solutions for a two-year consulting agreement.  

“We continue to expand our portfolio of products for integrated pest management, giving growers more tools to control diseases, improve plant health, and enhance grower return on investment,” said Marrone Bio Chief Executive Officer Dr. Pam Marrone.  “The Jet Ag product line delivers the kind of results we demand of our products: Proven performance, capacity for significant revenue growth and attractive gross margins.”

The products—which are used in specialty agricultural and field crops as well as greenhouse and irrigation applications—are expected to be a strong fit with Marrone Bio’s BioUnite strategy.  Jet Ag and Jet Oxide also can be used in post-harvest storage fogging, greenhouse surfaces/irrigation systems and agriculture irrigation water and drainage ditches.  Jet Ag is one of the leading products in the peroxyacetic acid (PAA) agriculture, turf, ornamentals and post-harvest markets.   

“We look forward to continuing our relationship with Jet Harvest, and anticipate both commercial and financial benefits from the addition of Jet Ag to our product portfolio, especially with our Regalia® and Stargus®  families of fungicides,” noted Kevin Hammill, chief commercial officer for Marrone Bio.  “Jet Ag gives us the opportunity to immediately expand into new markets with a product that has excellent performance and consistency.”

Industry Background

The global fungicide market totals in excess of $16.5 billion1. The agricultural disinfectant market totals $1.9 billion and is expected to grow to $2.1 billion by 20212.

1markets and markets; 2Phillips McDougall

About Marrone Bio Innovations     
Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the Company’s product pipeline.

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: TwitterLinkedIn and Instagram.

Marrone Bio Innovations Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date.  Examples of such statements include statements regarding the asset acquisition from Jet Harvest Solutions, the benefits to the Company of the transaction, and the potential benefits of the Company’s products and the products being acquired in the acquisition. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, adverse decisions by regulatory agencies and other relevant third parties, and any difficulty in integrating the acquired business.  Additional information that could lead to material changes in MBI’s performance is contained in its filings with the Securities and Exchange Commission.  MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

Marrone Bio Innovations Contacts:
Pam Marrone, CEO and Founder
Jim Boyd, President and CFO
Telephone: +1 (530) 750-2800
Email: Info@marronebio.com

MBII Investor Relations
Greg Falesnik, Managing Director
MZ Group – MZ North America
Main: 949-385-6449
MBII@mzgroup.us
www.mzgroup.us 

MBII Press Contact   
Kevin Hammill
Chief Commercial Officer
khammill@marronebio.com
1-530-750-2800

Primary Logo


ę GlobeNewswire 2019
All news about MARRONE BIO INNOVATIONS, INC.
06/03Marrone Bio Innovations Partners with ATP Nutrition to Distribute Stargus« Bi..
GL
05/28MARRONE BIO INNOVATIONS INCá : Change in Directors or Principal Officers, Submis..
AQ
05/21MARRONE BIO INNOVATIONSá : New Corteva Agriscience Naturally Derived Seed Treatm..
PU
05/13MARRONE BIO INNOVATIONSá : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
05/13MARRONE BIO INNOVATIONSá : Q1 Loss Narrows as Revenue Increases
MT
05/13MARRONE BIO INNOVATIONS INCá : Results of Operations and Financial Condition, Re..
AQ
05/13MARRONE BIO INNOVATIONSá : Earnings Flash (MBII) MARRONE BIO INNOVATIONS Reports..
MT
05/13MARRONE BIO INNOVATIONSá : Earnings Flash (MBII) MARRONE BIO INNOVATIONS Posts Q..
MT
05/13Marrone Bio Innovations Issues Shareholder Letter
GL
05/13MARRONE BIO INNOVATIONSá : Reports First-Quarter 2021 Financial Results
AQ
More news
Financials (USD)
Sales 2021 49,8 M - -
Net income 2021 -13,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -23,6x
Yield 2021 -
Capitalization 307 M 307 M -
Capi. / Sales 2021 6,16x
Capi. / Sales 2022 4,60x
Nbr of Employees 145
Free-Float 98,2%
Chart MARRONE BIO INNOVATIONS, INC.
Duration : Period :
Marrone Bio Innovations, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MARRONE BIO INNOVATIONS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 3,23 $
Last Close Price 1,75 $
Spread / Highest target 129%
Spread / Average Target 84,6%
Spread / Lowest Target 22,9%
EPS Revisions
Managers and Directors
NameTitle
Kevin R. Helash Chief Executive Officer & Director
Sue Cheung Chief Financial Officer
Robert A. Woods Chairman
Amit Vasavada Chief Technology Officer, Senior VP-R&D
Linda V. Moore Secretary, Chief Compliance Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
MARRONE BIO INNOVATIONS, INC.40.00%307
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.-9.94%11 638
THE SCOTTS MIRACLE-GRO COMPANY-5.11%10 526
ICL GROUP LTD39.12%8 953
PHOSAGRO54.17%8 650
UPL LIMITED78.88%8 589